Pharmaceutical Industry Information Portal

Philochem and Bracco Imaging announce collaboration on development of a small molecule

Philochem, a subsidiary of the Philogen Group, and Bracco Imaging On Tuesday announced that they have entered into a license and collaboration agreement to develop and commercialize a small organic molecule for imaging applications, with proven ability to selectively detect a variety of metastatic solid tumors in cancer patients, paving the way for a new approach to tumor diagnosis.

Philogen and Bracco share an Italian heritage and operate globally in the pharmaceutical and biotech sectors. Bracco and Philochem will pioneer the development of cutting-edge technologies for the discovery and optimization of small molecule ligands that enable unprecedented specificity and sensitivity for the imaging of solid tumors.

Prof. Dr. Dario Neri, Member of the Board of Philochem and CEO of the Philogen Group, commented:

We are extremely pleased to establish a new collaboration with Bracco Imaging, a leading global company in the image diagnostics field. This new collaboration will focus on the development and commercialization of a small molecule for imaging applications, which promises to improve the diagnosis, staging and monitoring of response-to-treatment for cancer patients. Both companies are committed to the development of the product and making it available to patients who may benefit from it.

Fulvio Renoldi Bracco, Vice-Chairman & CEO of Bracco Imaging said:

We are very excited about this collaboration with Philochem, a leader in the discovery and development of novel pharmaceutical and biopharmaceutical products. It demonstrates Bracco’s commitment to long-term value creation in medical imaging. Over the years, Bracco has built a portfolio of leading products across all imaging modalities and is continuing to invest in innovation to shape the future of precision imaging and improve people’s lives.

spot_img

Expert Articles

spot_img